201 institutions hold shares in Constellation Pharmaceuticals Inc. (CNST), with 800.64k shares held by insiders accounting for 1.67% while institutional investors hold 109.07% of the company’s shares. The shares outstanding are 47.63M, and float is at 47.22M with Short Float at 13.94%. Institutions hold 107.24% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Wellington Management Group, LLP with over 4.39 million shares valued at $126.56 million. The investor’s holdings represent 9.18% of the CNST Shares outstanding. As of Dec 30, 2020, the second largest holder is VR Adviser, LLC with 4.02 million shares valued at $115.69 million to account for 8.39% of the shares outstanding. The other top investors are Avoro Capital Advisors LLC which holds 2.95 million shares representing 6.16% and valued at over $84.96 million, while Column Group LLC holds 5.49% of the shares totaling 2.63 million with a market value of $75.65 million.
Constellation Pharmaceuticals Inc. (NASDAQ: CNST) is -23.19% lower on its value in year-to-date trading and has touched a low of $17.00 and a high of $50.90 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CNST stock was last observed hovering at around $21.60 in the last trading session, with the day’s gains setting it 0.52% off its average median price target of $50.00 for the next 12 months. It is also 70.51% off the consensus price target high of $75.00 offered by 11 analysts, but current levels are 7.83% higher than the price target low of $24.00 for the same period.
Currently trading at $22.12, the stock is -4.57% and -19.89% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.45 million and changing 2.41% at the moment leaves the stock -15.87% off its SMA200. CNST registered -35.70% loss for a year compared to 6-month gain of -2.60%. The firm has a 50-day simple moving average (SMA 50) of $28.29 and a 200-day simple moving average (SMA200) of $27.11.
The stock witnessed a -19.77% loss in the last 1 month and extending the period to 3 months gives it a -39.55%, and is -4.16% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.49% over the week and 6.40% over the month.
Distance from 52-week low is 30.12% and -56.54% from its 52-week high.
Constellation Pharmaceuticals Inc. (CNST) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Constellation Pharmaceuticals Inc. (CNST) is a “Buy”. 11 analysts offering their recommendations for the stock have an average rating of 2.00, where 2 rate it as a Hold and 1 think it is a “Overweight”. 8 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Constellation Pharmaceuticals Inc. is expected to release its quarterly report on 08/11/2021 and quarterly earnings per share for the current quarter are estimated at -$0.79.The EPS is expected to shrink by -37.30% this year.
Constellation Pharmaceuticals Inc. (CNST) Insider Activity
A total of 24 insider transactions have happened at Constellation Pharmaceuticals Inc. (CNST) in the last six months, with sales accounting for 13 and purchases happening 11 times. The most recent transaction is an insider sale by Reeve Emma, the company’s Chief Financial Officer. SEC filings show that Reeve Emma sold 6,260 shares of the company’s common stock on Feb 22 at a price of $37.60 per share for a total of $0.24 million. Following the sale, the insider now owns 0.0 shares.
Constellation Pharmaceuticals Inc. disclosed in a document filed with the SEC on Feb 19 that Reeve Emma (Chief Financial Officer) sold a total of 4,010 shares of the company’s common stock. The trade occurred on Feb 19 and was made at $37.71 per share for $0.15 million. Following the transaction, the insider now directly holds 0.0 shares of the CNST stock.
Still, SEC filings show that on Feb 18, Reeve Emma (Chief Financial Officer) disposed off 1,100 shares at an average price of $37.58 for $41343.0. The insider now directly holds 0 shares of Constellation Pharmaceuticals Inc. (CNST).